# Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer

> **NCT07093931** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 468 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** lobaplatin
- **DRUG:** carboplatin
- **DRUG:** Docetaxel or albumin paclitaxel
- **DRUG:** Trastuzumab
- **DRUG:** pertuzumab

## Key facts

- **NCT ID:** NCT07093931
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2027-08-01
- **Final completion:** 2030-08-01
- **Target enrollment:** 468 (ESTIMATED)
- **Last updated:** 2025-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07093931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07093931, "Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07093931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*